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Assembly and activation of the Hippo signalome
by FAT1 tumor suppressor
Daniel Martin1, Maria S. Degese1, Lynn Vitale-Cross1, Ramiro Iglesias-Bartolome 1,2,
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J. Guy Lyons 10,11,12 & J. Silvio Gutkind1,3,4
Dysregulation of the Hippo signaling pathway and the consequent YAP1 activation is a
frequent event in human malignancies, yet the underlying molecular mechanisms are still
poorly understood. A pancancer analysis of core Hippo kinases and their candidate regulating
molecules revealed few alterations in the canonical Hippo pathway, but very frequent genetic
alterations in the FAT family of atypical cadherins. By focusing on head and neck squamous
cell carcinoma (HNSCC), which displays frequent FAT1 alterations (29.8%), we provide
evidence that FAT1 functional loss results in YAP1 activation. Mechanistically, we found that
FAT1 assembles a multimeric Hippo signaling complex (signalome), resulting in activation of
core Hippo kinases by TAOKs and consequent YAP1 inactivation. We also show that
unrestrained YAP1 acts as an oncogenic driver in HNSCC, and that targeting YAP1 may
represent an attractive precision therapeutic option for cancers harboring genomic alterations
in the FAT1 tumor suppressor genes.
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Persistent activation of YAP1 and its paralog WWTR1 (alsoknown as TAZ), is a hallmark of multiple human malig-nancies1–3. However, the molecular mechanisms driving
YAP1 activation in cancer are still poorly defined. Genetic ana-
lysis in Drosophila revealed that the activity of Yorkie (Yki), the
Drosophila YAP1 ortholog, is controlled by an intricate molecular
network collectively known as the Hippo pathway4. Mammalian
cells, however, appear to have evolved to fine tune the activity of
YAP1 by multiple signals under physiological conditions,
including growth promoting and inhibitory factors, matrix
composition, cell–cell contact, cell density, mechanical pertur-
bation, and metabolic conditions, to name but a few5. The highly
conserved core Hippo kinase cascade is initiated by the activation
of the mammalian Hippo orthologs, MST1 and MST2 (MST1/2),
which are associated with the adaptor protein WW45/SAV1.
MST1/2 phosphorylates and activates LATS1/2 kinases, referred
to herein as LATS, in complex with MOB. In turn, active LATS
phosphorylates and inhibits the mammalian transcription co-
activator YAP1 and its related protein TAZ, which are degraded
or excluded from the nucleus, thereby preventing their associa-
tion with their target transcription factors, including TEAD
family members6. In light of the crucial role of MST1/2 and LATS
in YAP1 regulation, there are surprisingly few recurrent altera-
tions in these core Hippo pathway components in cancer1.
Indeed, there are only a few examples of known YAP1 regulating
genes altered in cancer, which include LATS2 and an upstream
Hippo pathway component, NF2, in malignant mesothelioma
(35% and 50%, respectively)7, and inherited NF2 mutations and
microdeletions in neurofibromatosis type 28, overall accounting
for a small fraction of human malignancies displaying YAP1
hyperactivity.
Here, we identify the alteration of FAT1 as a recurrent event in
human cancer acting in coordination with other YAP1 activating
mechanisms. We found that in normal conditions, FAT1 enables
the assembly of a signaling complex including the canonical
Hippo signaling components leading to phosphorylation and
inactivation of YAP1. Gene deletions or truncating mutations of
FAT1 result in impaired regulation of YAP1 activity. The high
prevalence of these alterations underscore the crucial role of this
oncogenic mechanism in human malignancies. Finally, we show
that targeting unrestrained YAP1 may represent an attractive
precision therapeutic option for cancers harboring genomic
alterations in the FAT1 tumor suppressor genes.
Results
Widespread alterations in FAT1 in cancer. As an approach to
explore the molecular mechanisms resulting in tumor-associated
YAP1 activation, we investigated the presence of genomic altera-
tions in all human orthologs of Drosophila Hippo pathway com-
ponents in a large panel of 38 distinct cancers sequenced by The
Cancer Gene Atlas consortium (TCGA, 14729 neoplastic lesions,
Supplementary Fig. 1a)9. Among these genes, a recently developed
mutation significance method (MutSigCV), which provides a sta-
tistical metric to identify driver candidates in cancer with respect to
the gene nucleotide length and the background mutation rate of
each cancer analyzed10, recognized only FAT1 to be significantly
mutated when conducting a pancancer analysis (Supplementary
Fig. 1a and b, and see below, Fig. 1a). Of interest, some members of
the canonical Hippo pathway also achieved statistical significance
when analyzing each cancer type individually (Supplementary
Fig. 1c), suggesting their potential role in YAP activation in these
specific cases. In addition to mutations, we also studied somatic
copy number alterations predicted by the GISTIC2.0 method11.
We found many known or candidate YAP1 and FAT regulators
or associated transcription factors to be significantly amplified
(MST2/STK3, TEAD4, TAZ/WWTR1, and YAP1) or deleted
(DCHS2, FAT1, FAT4, LATS1/2, TEAD1, TEAD2, and KIBRA/
WWC1) (Supplementary Fig. 1b). However, most of these copy
number variations involve large genomic segments containing
additional genes, thus precluding the identification of these Hippo
pathway genes as candidate onco-drivers. Indeed, only the deletion
of FAT1 and WWC1 and amplification of YAP1 appeared to be
highly significant and focal, likely reflecting the specificity and
biological impact of their gene copy variations.
Remarkably, both analyses converged in the recurrent and
highly significant alterations of FAT1, such as somatic mutations
and focal gene deletions, in multiple human malignancies
(Fig. 1a, b). Some of these frequent genomic alterations in
FAT1 have been recently well documented12,13. However,
whether FAT1 controls the Hippo pathway is unclear, as its
deficiency has been proposed to result in aberrant WNT signaling
by increasing the availability of cytosolic β-catenin, similar to
classical cadherins13,14. In this regard, we found that FAT1
mutations and gene copy loss occur in many cancers, such as
squamous cell carcinomas of the head and neck (29.8%), lung
(18.5%), and cervix (9.9%) (Fig. 1b), which are known to retain
expression of classical E-cadherin, hence making it improbable
that loss of FAT1 will solely contribute to cell–cell contact
mediated regulation of β-catenin.
Coordinated alteration of YAP1 and FAT1 in HNSCC. To
begin addressing FAT1 functions in cancer, we focused on HNSCC,
the cancer type in which FAT1 is most frequently mutated (Fig. 1b)
and which displays characteristic Hippo signaling dependency,
YAP1 overactivity, and frequent YAP1 gene amplification9,15. We
posit that these findings may provide an opportunity to investigate
the mechanism by which FAT1 regulates YAP in a biologically
relevant cancer. The vast majority of FAT1 mutations in HNSCC
are inactivating by virtue of resulting in early termination and likely
truncated gene products (Fig. 1c). Moreover, expression of FAT3
and FAT4 is limited in most normal oral tissues and HNSCC
lesions (Supplementary Fig. 1c). This simplified our analysis by
reducing the chance of potential functional compensation between
FAT family members, making HNSCC the ideal tumor type to
investigate FAT1 function. Remarkably, the use of our recently
developed REVEALER16 computational approach identified FAT1
truncating mutations as the top genomic abnormality com-
plementary of YAP1 gene amplification significantly associated with
YAP1 activity (p= 0.01), as measured by CTGF and CYR61 over-
expression, out of a total of 1589 candidate genomic abnormalities
in the large cohort (n= 504) of HNSCC (Fig. 1d). This unbiased
approach supported the potential role of FAT1 in the regulation of
YAP1, and also identified NOTCH1 mutations and CYC1 amplifi-
cation, which achieved nearly statistical significance, as additional
candidate YAP1 regulating events in HNSCC.
To begin dissecting the molecular mechanisms controlled by
FAT1 we next studied the gene expression profiles of 264 HNSCC
tumors from the TCGA. We stratified tumor cases containing
FAT1 and FAT2 alterations, including mutations, copy loss
alterations or loss of expression (n= 188) and compared them to
those exhibiting unaltered FAT1 and FAT2 (n= 76). Analysis of
366 differentially expressed genes between these groups (Supple-
mentary data 1) revealed that the genes upregulated in the FAT
altered group were enriched for genes containing TEAD2 and
TCF4 binding sites in their promoter regions (Fig. 1e and
Supplementary data 2), and thus potentially regulated by YAP1 or
β-catenin, the latter consistent with prior reports13,14. We further
confirmed the status of YAP1 protein activation in a panel of 111
primary HNSCC lesions and 5 normal tissues, and observed that
the number of cells displaying the active, nuclear localized form
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of YAP1 positively correlated with disease progression and
malignancy. Indeed, in poorly differentiated HNSCC lesions
YAP1 activation is generalized (Fig. 1f, g). This trend is similar to
that observed in other tumor types such as lung squamous
carcinoma, skin melanoma, and cervical cancer (Supplementary
Fig. 2), whereas YAP1 activation is absent in most sarcomas and
lymphoid tumors, which, coincidentally, display low alteration
rates in FAT genes (<5%).
FAT1 regulates YAP1 in mammals. We next explored the
potential link between FAT1 alterations and YAP1 activation
using HEK293 cells, a widely used model system to study Hippo
signaling and YAP1 function. We began investigating the impact
of siRNA-mediated FAT1 and FAT2 knockdown, mimicking
FAT1/2 inactivation, and observed a robust YAP1 nuclear
translocation (Fig. 2a). This resulted in the YAP1-dependent
increased expression of the YAP1 target genes CTGF and CYR61,
d
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as it was blunted by YAP1 knockdown (Fig. 2b). In contrast,
FAT1/2 knockdown in these cells did not induce the expression
of the β-catenin target AXIN217. Knockdown of FAT1/2 resulted
in Hippo pathway inactivation, as judged by a marked decrease in
the levels of phospho-MST1 (pMST1) and phospho-YAP1
(pYAP1) (Supplementary Fig. 3a). We confirmed these findings
in human oral keratinocytes (NHOK) isolated from healthy
volunteers18 (Supplementary Fig. 3b−d). FAT1/FAT2 knockdown
resulted in increased YAP1 nuclear accumulation and increased
expression of CTGF and to a lesser extent AXIN2, supporting a
role of FAT1/2 in the regulation of both YAP1 and WNT/β-
catenin pathways in these normal cells. FAT1/2 knockdown led to
increased growth of these normal epithelial cells, as reflected by
their nearly doubled proliferation rate, which was blunted by the
concomitant YAP1 knockdown (Supplementary Fig. 3d).
As a complementary approach to knocking down FAT1/2
expression, we next studied the impact of FAT1 overexpression in
HEK293 cells. To overcome the limitation of the sheer length of
the FAT1 gene, as previously noted12,13, we used as a molecular
tool the expression of the FAT1 intracellular domain (ICD) as
this domain has been shown in Drosophila to mediate most of ft
signaling activity19. We engineered chimeric constructs in which
the very large extracellular portion of FAT1 was replaced by the
extracellular domain of the human CD4 molecule, in which the
transmembrane and juxtamembrane regions were provided by
either FAT1 (CD4-FAT1-TM/ICD) or CD4 (CD4-FAT1-ICD)
(Fig. 2c). These chimeric constructs were correctly expressed and
membrane-localized in HEK293 cells, as judged by western blot
and FACS analysis (Fig. 2d, and see Fig. 2f). Strikingly, when
overexpressed in HEK293 cells, both FAT1 chimeras but not
CD4ext control were sufficient to induce the downregulation of a
YAP1-regulated TEAD luciferase reporter (Fig. 2e) and nuclear
exclusion of YAP1 (Fig. 2f), which is consistently nuclear
localized in proliferating, non-confluent HEK293 cells. The
inactivation of YAP1 by expression of the CD4-FAT1 chimeric
constructs was further confirmed by qPCR analysis of CTGF and
CYR61 (Fig. 2g).
FAT1 forms a molecular complex with Hippo pathway mem-
bers. Because YAP1 nuclear localization is regulated by the
activity of the Hippo signaling pathway, we studied the regulation
by FAT1 of the phosphorylation status of the Hippo pathway core
components. As shown in Fig. 3a, expression of CD4-FAT1-TM/
ICD in HEK293 induced the robust phosphorylation of the
kinases MST1 and LATS1, as well as MOB1A and YAP1 without
seemingly altering total YAP1 levels, therefore ruling out the
degradation of YAP1 as a mechanism by which FAT1 regulates
YAP1 activity. To dissect the underlying molecular mechanism,
we used a panel of CRISPR/Cas9 engineered HEK293 cells
lacking the expression of the critical Hippo pathway components
LATS1/2, NF2, and MST1/220. As shown in Fig. 3b, the ability of
FAT1 to stimulate YAP1 is strictly dependent on the presence of a
completely functional Hippo signaling complex, as removal of
any one of its components resulted in the inhibition of pYAP1
accumulation caused by the FAT-1 ICD. While MST1 activation
may result from autophosphorylation21, recent reports implicat-
ing the TAOK1/2/3 kinases in the initiation of the Hippo kinase
cascade in Drosophila22,23 prompted us to investigate if these
kinases play a role in the FAT1-initiated pathway. As show in
Fig. 3c, the triple knockdown of TAOK1/2/3 completely impaired
YAP1 phosphorylation induced by CD4-FAT1-TM/ICD expres-
sion in HEK293 cells, indicating that TAO kinases are strictly
required for Hippo pathway activation triggered by FAT1.
We then investigated the ability of FAT1 ICD to physically interact
with members of the Hippo pathway by using GST-FAT1-ICD
fusion protein purified from bacteria (Supplementary Fig. 4a) to
perform pulldown experiments using cellular lysates as
indicated in Fig. 3d, using GST-LATS142–704 as a positive control.
The ICD of FAT1 strongly interacted with MST1, SAV1, NF2,
AMOT, and PATJ, which are all key Hippo regulatory
components, whereas it did not interact with YAP1, and
TAOK-1 (Supplementary Fig. 4b) and had only a very weak
interaction with TAZ. The direct interaction of FAT1-ICD with
LATS1 was not evaluated in this experiment due to cross-
reactivity of the LATS1 antibody with bacterially expressed GST-
FAT1-ICD; however, this interaction was demonstrated in cells
in vivo (see below). Of interest, FAT1-ICD binds to total and
phosphorylated MST1, but GST-LATS142-704 failed to interact
with pMST1. Deletion mutagenesis analysis of the FAT1-ICD
showed that the presence of the first 58 amino acids were
sufficient to bind strongly to MST1/2, whereas the last 186 amino
acids were able to interact with MST1 independently as well,
albeit to a much lesser degree (Fig. 3e). LATS1142-704 and FAT1-
ICD associated equally well with SAV1, NF2 and PATJ; however
in the case of AMOT, it interacted much more strongly with
FAT1-ICD. Finally, unlike FAT1-ICD, LATS1142-704 interacted
strongly with YAP1 and TAZ, and at least a portion of YAP1 was
phosphorylated YAP1S127. These results indicate that FAT1-ICD
can associate with a multimeric complex containing core Hippo
signaling components.
To further investigate how the formation of the FAT1-Hippo
signaling complex is coordinated, we performed siRNA studies to
determine their molecular hierarchy. We successfully knocked
down the expression of several key Hippo pathway components
(Supplementary Fig. 4c) and studied its impact on complex
assembly. As shown in Fig. 3f, MST1 knockdown prevented the
efficient interaction of FAT1-ICD with all other members of the
complex. On the other hand, LATS1/2 knockdown partially
prevented the interaction of FAT1-ICD with SAV1, AMOT and
NF2, while AMOT knockdown only affected NF2 binding.
Therefore, we concluded that MST1 is an essential component of
the complex, likely mediating the direct interaction with
FAT1-ICD and promoting the assembly of a multiprotein
complex including also LATS, SAV1, NF2, AMOTl, and PATJ
(Fig. 3d).
We next sought to confirm the physical interaction of MST1
with FAT1 in vivo. We were unable to consistently detect
interaction of CD4-FAT1-TM/ICD with members of the Hippo
cascade by standard co-immunoprecipitation and western blot-
ting. We suspected that the failure of FAT1-TM/ICD to co-
immunoprecipitate Hippo pathway components was likely due to
the labile nature of the FAT-Hippo signaling complexes and their
disruption in the presence of the detergent concentrations
required for achieving the efficient extraction of CD4-FAT1-
TM/ICD from the plasma membrane. Indeed, we readily
visualized the interaction of CD4-FAT1-TM/ICD with LATS,
NF2, MST1, SAV, and MOB1A upon pretreatment of the cells
with a reversible cross linker, dithiobis succinimidyl propionate
(DSP), prior to CD4-mediated immunoprecipitation, as shown in
Supplementary Fig. 5a. Aligned with our in vitro data, this
interaction is dependent on MST1/2, as siRNA-mediated knock-
down of MST1/2 readily abolished the formation of immuno-
precipitable complexes. Moreover, taking advantage of a
monoclonal antibody recognizing FAT1 extracellular region24,
we observed that endogenous FAT1 associates with the core-
Hippo kinase complex, as judged by its co-immunoprecipitation
with FAT1 in DSP cross-linked cells, but not after FAT1
knockdown (Fig. 3g). Supporting the role of FAT1 in Hippo
complex assembly, endogenous MST1 co-immunoprecipitates
with NF2 and LATS/SAV primarily in CD4-FAT1-TM/ICD
expressing cells, whereas MST1-MOB1A complex formation does
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not require FAT1 (Supplementary Fig. 5b). Taken together, these
results indicate that the FAT1 ICD interacts with and facilitates
the assembly of the core Hippo signaling complex, and that this
interaction may induce the activation of Hippo kinases by
TAOKs, thereby providing a direct molecular mechanism linking
FAT1 to YAP1 phosphorylation and inactivation.
YAP1 as a molecular therapeutic target in HNSCC. To explore
whether FAT1 alterations and its associated downstream molecular
signaling play a role in tumorigenesis we used representative
HNSCC-derived cells displaying prototypical FAT1 alterations as
evidenced by exome sequencing of a large cell panel25, and iden-
tified SCC25 (FAT1 copy loss), CAL27 (heterozygous FAT1 copy
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loss), and CAL33 (hemizygous FAT1 K3504X mutation and loss of
the remaining allele) as displaying abnormal levels of FAT1 protein
compared to NOKs exhibiting wild-type FAT1 (Fig. 4a). We sought
to restore FAT1 function in tumorigenic HNSCC cells (CAL33 and
CAL27) by generating stable cell lines expressing the CD4-FAT1-
TM/ICD chimeric construct or its control (CD4ext). The appro-
priate expression and localization of these constructs was confirmed
by FACS (Fig. 4b and Supplementary Fig. 6b) and resulted in
decreased YAP1 activity as depicted by reporter assay (Fig. 4c) and
qPCR of the CTGF and CYR61 transcriptional targets (Fig. 4d).
Remarkably, expression of CD4-FAT1 ICD, but not its controls,
displayed reduced cell proliferation (Supplementary Fig. 6a) in vitro
and abolished tumorigenesis in vivo (Fig. 4e and Supplementary
Fig. 6c). These transcriptional and biological effects of CD4-FAT1-
TM/ICD were both rescued by overexpression of YAP1 or its
mutant that cannot be phosphorylated by LATS (Fig. 4f and Sup-
plementary Fig. 6d, e), supporting that YAP1 function is tightly
regulated by FAT1.
As FAT1 mutations may ultimately render cancer cells
dependent on YAP1 function, we next knocked down YAP1
expression using tetracycline-inducible YAP1 shRNA lentiviruses
in CAL27 and CAL33 cells, and in tumorigenic HN12 that display
normal FAT1 levels (Fig. 4a) but harbor YAP1 gene copy gain25.
Successful knockdown of YAP1 was confirmed by western blot
(Supplementary Fig. 6f and 8a). Knockdown of YAP1 resulted in
significantly smaller spheroid growth in these HNSCC cells
(Fig. 4g, and Supplementary Fig. 8b), reduced GAL4-TEAD
reporter expression (Fig. 4h and Supplementary Fig. 6g and 7c)
and 3–5-fold increase in basal apoptosis (Fig. 4i and Supplemen-
tary 6h). We evaluated the impact of YAP1 downregulation
in vivo in a tumor xenograft model. As shown in Fig. 4j and
Supplementary Fig. 6i and 7d, two independent YAP1 shRNAs
completely abrogated tumor growth in CAL33 and CAL27 cell
lines, and strongly inhibited tumor growth of HN12 HNSCC
cells, which correlated with decreased proliferation as depicted by
BrdU incorporation (Fig. 4k, l, Supplementary Fig. 6j), and in
some cells (CAL33), increased expression of the epithelial
differentiation marker Cytokeratin 10 (CK10) (Fig. 4k, l).
The dramatic impact of YAP1 knockdown in HNSCC
tumorigenesis prompted us to evaluate the possibility of the
pharmacological intervention on YAP1 as a therapeutic venue in
HNSCC. Although there are not yet specific YAP1 inhibitors, the
U.S. Food and Drug Administration (FDA) approved drug
Verteporfin (VP) was identified as a disruptor of the interaction
between YAP1 and the TEAD2 transcription factor in a small
molecule inhibitor screen, thereby inhibiting YAP1 signaling
output and reverting the impact of YAP1 overexpression or
NF2 inactivation in vivo26. First, we evaluated the effect of VP on
cell viability in vitro and determined that the IC50 for CAL27,
CAL33, and HN12 is in the low µM range (Fig. 5a and
Supplementary Fig. 8a and 8d) aligned with its previously
reported activity26. This correlated with a reduction in the mRNA
levels of the YAP1 transcriptional targets CYR61, CTGF, and
FSTL, while YAP1 mRNA levels remained unaffected and hence
served as a control (Fig. 5b and Supplementary Fig. 8e),
supporting the idea that VP causes the inhibition of YAP1
transcriptional activity. Moreover, VP reduced the proliferation
of HNSCC and tumor spheroid formation in vitro (Fig. 5c, e, and
Supplementary Fig. 8b and 8f) and caused apoptosis in HNSCC
cells in vitro (Fig. 5d and Supplementary Fig. 8c). We then
evaluated the impact of VP in vivo in HNSCC cells in flank and
oral orthotopic xenograft models. In both cases, VP reduced
tumor growth and cancer cell proliferation when administered
daily (Fig. 5f–k), suggesting that YAP1 is an attractive therapeutic
target in human HNSCC and likely other human malignancies.
Discussion
The recent advance on massively parallel sequencing techniques
has afforded an unprecedented wealth of information about the
genetic makeup of human cancer. The emerging information
confirmed the preponderant roles of many classical tumor sup-
pressors and oncogenes while some other less studied molecules
have been brought under the spotlight. Using HNSCC as an
example, this cancer type displays widespread genetic alterations
that include inactivating mutations of the tumor suppressor TP53
(70% of the cases) and mutations, homozygous deletions and
promoter methylation of CDKN2A (49%), which are believed to
be prerequisites for tumor formation27. This requirement of
tumor suppressor inactivation can be bypassed by HPV infec-
tion27,28. Recurrent mutation and amplification of PIK3CA (35%)
and to a lesser extent HRAS (4%) mutations have emerged as the
most frequent oncogenic drivers in both HPV- and HPV+
HNSCC, with other potential oncogenic events including EGFR,
CCND1 overexpression, or PTEN inactivation27,28. Here, we
provide evidence that inactivation mutations and genomic
alterations in FAT1 results in YAP1 activation via inactivation of
the Hippo signaling pathway, thereby contributing to the pro-
gression of HNSCC and likely multiple other human malig-
nancies displaying unrestrained YAP1 function.
Our analysis identified genomic alterations in members of the
canonical Hippo pathway, including LATS1 and NF2 in some
cancers, whose potential role in YAP activation warrants further
investigation in each individual cancer type. Remarkably, FAT1
mutations and focal gene deletions resulting in the loss of its
protein product appear to be widespread. However, whether
human FAT1 regulates the Hippo pathway has been much less
clear, and if so its underlying mechanism was not known. Most
Fig. 3 The intracellular domain of FAT1 interacts with and activates the Hippo kinase signalome. a Representative western blots against Hippo pathway
components in lysates of exponentially growing HEK293 CD4ext and CD4-FAT1-TM/ICD stable cells. Control, parental HEK293 cell line. b Analysis of
YAP1 phosphorylation after transient transfection with CD4 control or CD4-FAT1-TM/ICD chimera in WT or the corresponding CRISPR/Cas9 sgRNA
engineered knockout HEK293 cells as indicated. HA-YAP1 immunoprecipitates were analyzed by phos-tag phosphorylation affinity shift electrophoresis
and YAP1 western blotting. Retarded (phosphorylated) YAP1 is indicated by arrowheads. A representative blot is shown. c Analysis of YAP1
phosphorylation after transient cotransfection with Flag-YAP1 and CD4 control or CD4-FAT1-TM/ICD chimera in HEK293 cells pretreated with control (C)
or TAOK1/2/3 siRNA (TAOKs) as indicated. Flag-YAP1 immunoprecipitates were analyzed by phos-tag electrophoresis and YAP1 western blotting.
Retarded (phosphorylated) YAP1 is indicated by arrowheads. A representative blot is shown. d On the left, a scheme depicting the GST fusion proteins
indicating the approximate location of functional motifs present in FAT1 and LATS1 and the subsequent GST-pulldown assay. On the right, representative
western blots of pulldown experiments using GST fusion proteins and HEK293 total cell lysates. e Summary of mutant FAT1 ICD constructs (PPXY and
PDZ binding site) and the depicted deletions and their ability to bind MST1 as assessed by pulldown assay. f siRNA-mediated knockdown on HEK293 of the
different components of the Hippo signaling pathway and subsequent GST-FAT1-ICD pulldown on whole cells lysates. g Endogenous FAT1
immunoprecipitation by a monoclonal antibody recognizing is extracellular region. Exponentially growing HEK293 were transfected with FAT1 and
FAT2 siRNAs for 48 h and then treated for 2 h at 4 °C with DMSO (−) or the reversible crosslinker DSP (+) prior to cell lysis and immunoprecipitation
with anti-FAT1. Representative western blots are shown
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prior studies on YAP1 regulation in mammals have focused on
the role of FAT4 due to its genetic relatedness to drosophila ft19,
but the role of FAT1 and other FAT members in mammals
during development is less dramatic than ft in drosophila. In this
regard, it is now evident that the regulation of the Hippo pathway
has diverged from arthropods to vertebrates, likely to accom-
modate the unique developmental, physical and physiological
features of both phyla5. FAT1 regulates the development and
function of certain organs such as the kidney, while knockdown
experiments in mice and rat suggest that FAT1 has an important
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role in the development of the central nervous system (CNS)29,
and acts upstream of TAZ in neural differentiation30. Because
alterations in FAT1 KO mice occur with a variable penetrance, it
is possible that other FAT members may compensate for FAT1
loss, particularly in tissues such as the CNS during development,
in which all FAT family members are consistently expressed31,
likely precluding the display of stronger phenotypes. Indeed, our
analysis identified MST/Hippo binding sites in FAT1 ICD in
areas that are conserved in other FAT members, thus providing a
potential structural basis for their redundancy. As FAT expres-
sion levels drop in adult tissues32, it is possible to hypothesize that
this mechanistic compensatory effect might be reduced in cancers
arising during adulthood. For example, disruption of FAT1
function could be sufficient to dysregulate Hippo signaling in the
squamous epithelium, as this tissue expresses FAT3 and FAT4
poorly and FAT2 might not be sufficient to compensate FAT1
deficiency fully.
Overall, our oncogenomic and functional analyses support the
role of FAT1 in cancer as a tumor suppressor acting upstream of
YAP1. Of interest, this raises the possibility that FAT1 may con-
trol β-catenin, as previously reported13, and YAP1 independently.
Alternatively, FAT1 deficiency may promote β-catenin activation
indirectly through a recently described mechanism downstream
from YAP133. Further studies re-expressing full length FAT1 and
its deletion mutants in FAT1 defective cells may facilitate
addressing these exciting possibilities, as well as extend our ana-
lysis using FAT1 ICD chimeras. Mechanistically, we show that
chimeric and endogenous FAT1 signals to YAP1 by its direct
interaction with MST1 and the consequent association with a
multimeric signaling complex including the core Hippo pathway
kinases and their regulatory and scaffolding molecules, such as
AMOT and NF2. This, in turn, may result in the activation of
MST1 by TAOKs and the subsequent phosphorylation of LATS
and YAP1 (Fig. 5l). How precisely FAT1 association to MST1 may
lead to its phosphorylation by TAOKs is not fully understood. We
can speculate that the physical interaction between MST1 and
FAT1 and the assembly of the Hippo kinase complex at the
plasma membrane may relieve MST1 from an auto inhibitory
mechanism21, thereby enabling its recognition and phosphoryla-
tion by TAOKs, ultimately leading to the activation of the Hippo
kinase cascade (Fig. 5l). This and other possibilities by which
FAT1 may regulate YAP, including the recruitment of TAOKs to
the proximity of MST1 by additional yet to be identified Hippo
signaling complexes, or FAT1 and TAOK acting on other Hippo
pathway components warrant further investigation.
The high frequency of alterations in the FAT gene family can
now provide a widespread mechanism contributing to the
recurrent activation of YAP1/TAZ in human malignancies, in
addition to other more restricted processes in other tumor
types34–36 (Fig. 5l). In turn, targeting YAP1/TAZ function or
their relevant downstream targets poses a very attractive ther-
apeutic venue that also justifies further investigation. In this
regard, while VP cannot be considered a specific YAP1 inhibitor
and is likely to impact several other molecular targets in addition
to blocking TEAD-YAP1 interactions37,38, this FDA-approved
agent decreased the expression of YAP1-regulated genes and its
administration resulted in increased apoptosis, and decreased
proliferation and HNSCC tumorigenesis in vivo, mimicking
YAP1 knockdown in these cells. These observations provide
further support of the potential benefits of the use of pharma-
cological inhibitors of YAP1 in cancer. Specifically for HNSCC,
our results indicate that the frequent alteration of FAT1 might
result in defective Hippo signaling and unrestrained YAP1
activity, thus raising the possibility that molecular therapies tar-
geting YAP1 or its downstream targets may represent an attrac-
tive precision medicine therapeutic option for the treatment of
this and other malignancies harboring genomic alteration in the
FAT family of tumor suppressor genes.
Methods
Antibodies and reagents. Antibodies against YAP1, pMST1T183, MST1,
pMOB1T12, MOB1, pLATS1S909, LATS1, LATS2, AMOT, NF2, SAV1, PATJ,
pYAPS127, pYAPS397 (1:2000), and Tubulin-HRP (1:10000) were purchased from
Cell Signaling Technology (Beverly, MA). A monoclonal antibody against FAT1
(NTD14, 1:1000) against the nz-terminal region has been recently described24.
Cytokeratin 10 rabbit polyclonal antibody was purchased from Covance (Prince-
ton, NJ) (1:1000), anti-BrdU (Bromodeoxyuridine) Rat monoclonal antibody was
from Accurate (Westbury, NY). Anti-TAZ antibody was purchased from Santa
Cruz (Santa Cruz, CA)(1:2000). Antibodies anti-CD4 (OKT4) was from
eBioscience (San Diego, CA)(1:2000). Verteporfin (VP) was purchased from USP
(Rockville, MD).
Cell lines, culture conditions and transfections. CAL27, CAL33, and HN12 cell
lines were obtained from the NIDCR Oral and Pharyngeal Cancer Branch cell
collection25. Their identity was confirmed by STR profiling and were tested free of
mycoplasma infection. HEK293 were purchased from ATCC (Manassas, VA).
CAL27, CAL33, HN12, and HEK293 cell lines were cultured on DMEM (D-6429,
Sigma-Aldrich, St. Louis, MO), 10% fetal bovine serum, 5% CO2, at 37 °C. Normal
Human Oral Keratinocytes (HNOK) lines were prepared as described before39 and
grown on Defined Keratinocyte-SFM with supplements and antibiotics (Life
Technologies, Carslbad, CA). LATS1/2-, MST1/2-, or NF2-deficient HEK293A cells
were created through the CRISPR/Cas9 system as described before20. SiRNAs
SMARTpool ON-TARGETplus for FAT1, FAT2, SAV1, NF2, non-targeting con-
trol, and YAP1-inducible lentiviral shRNAs, clones V2THS_65509 and
V2THS_247011 were from GE Healthcare (Lafayette, CO). siRNAs for MST1 were
purchased from IDT (DsiRNA Duplexes human MST1 5′-AGUUGUCGCAAUU
AAACA 5′-AGGUACUUGUUUAAUUGC, IDT, Coralville, IA). SiRNAs for
LATS1 and LATS2 were from Sigma (MISSION siRNA human LATS1
SASI_Hs01_00046128, siRNA human LATS2 SASI_Hs01_00158803)40.
Fig. 4 YAP1 is required for HNSCC survival and proliferation in vitro and in vivo. a Analysis of FAT1 expression in a panel of epithelial cells, including
HNSCC. b Expression of CD4ext and CD4-FAT1-TM/ICD chimera in the HNSCC cell line CAL33 by CD4 FACS analysis. c TEAD-Luciferase reporter assay
in CAL33 cells transiently transfected with the CD4-FAT1 chimeric constructs. Luciferase expression was evaluated in exponentially growing cultures 36 h
after transfection. Bars represent mean Renilla-normalized luciferase expression ± SEM (N= 4). d Quantitative PCR depicting gene expression levels of the
YAP1 transcriptional targets CTFG and CYR61 in CAL33 stably expressing the CD4-FAT1 ICD constructs. Bars represent the GAPDH-normalized mean ±
SEM (N= 3). e In vivo xenograft assay. One million CAL33 cells expressing indicated constructs were injected in nu/nu mice. Data points represent mean
volume (N= 10 tumors per group) ± SEM. f YAP-rescue experiments. In vivo flank xenograft assay as in (e) using CAL33 expressing CD4-FAT1-TM/ICD
and control or the indicated YAP expression vector. Data points represent mean volume (N= 10 tumors per group) ± SEM. g Spheroid formation assay of
stable CAL33 shRNA control and YAP1 shRNA cell lines. Representative pictures are shown on top and diameter quantifications (>200 colonies per group)
are shown below. Black lines represent mean ± SEM. h CAL33 stably expressing control and YAP1 shRNAs were stimulated with doxycycline for five days
(1 µg/ml) and then transfected with a 8xTEAD-luciferase reporter. Renilla-normalized reporter activity is expressed as % of control. Bars represent
mean ± SEM (N= 4). i Apoptosis assay by propidium iodide staining of CAL33 cell lines expressing control or YAP1 shRNA after 5d of Doxycycline
stimulation. Bars represent mean ± SEM (N= 4). j In vivo xenograft assay. One million cells were injected in nu/nu mice. Animals were fed Doxycycline
food (6 g/Kg) ad libitum 24 h h after tumor cell injection for the duration of the experiment. Data points represent mean volume per group (N= 10 tumors)
± SEM. k Representative immunohistochemical stainings of CAL33 tumors from panel (j). In the Cytokeratin 10 (CK10) panels the dotted red line delimits
the proliferating front of the tumor. Scale bar, 100 µm. l Automated histological quantification of stainings in (k), bars represent mean ± SEM (N= 3).
**P < 0.01, ***P < 0.001 (One-way ANOVA)
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Immunohistochemistry. H&E stained paraffin sections were used for histo-
pathological evaluation. For immunohistochemistry, 5-μm unstained paraffin
sections were deparaffinized in three changes of SafeClear II (ThermoFisher Sci-
entific, Waltham, MA), 5 min each, and the hydrated with graded alcohols (100°,
95°, 70°), two changes each, 5 min each. The endogenous peroxidase was blocked
by incubating for 30 min in 3% H2O2 in 70° ethanol. Antigens were retrieved with
10 mM citric acid (2.1 g/L) in a microwave oven, 2 min at 100% power, followed by
18 min at 20%. The slides were allowed to cool for 15 min and washed extensively
with distilled water, followed by three changes of PBS, 5 min each. After blocking
with 2.5% BSA in PBS at room temperature, for 30 min, the slides were incubated
overnight at 4 °C with the appropriate primary antibodies diluted in 2.5% BSA in
PBS. The slides were then washed with PBS, 3 × for 5 min, and successively
incubated biotinylated anti-rabbit/rat immunoglobulins, 1:400 in blocking buffer at
room temperature, for minutes, washed with PBS 3 × for 5 min each, and incubated
with ABC complex (Vector Labs, Burlingame, CA), 30 min at room temperature.
The slides were extensively washed with PBS; the reaction was developed with
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3,3′-Diaminobenzidine under microscopic control and stopped with distilled water.
The slides were the counterstained with Hematoxylin and washed 15 min in
running tap water to bluish, dehydrated in graded alcohols (70°, 95°, 100°), cleared
in SafeClear II and mounted in Permount mounting media (ThermoFisher Sci-
entific). The histological slides were processed and developed at the same time to
minimize inter-assay variability. All stained slides were scanned at ×40 using an
Aperio CS Scanscope (Aperio, Vista, CA) and quantified using the available Aperio
algorithms.
Immunofluorescence and image quantification. NOK were seeded on the cov-
erslips coated with collagen, 293 cells were seeded on coverslips coated with poly-D
lysine (Sigma-Aldrich, St. Louis, MO). For immunofluorescence, the cells were
washed with ice-cold PBS and fixed with 3.2% paraformaldehyde in PBS. Then the
cells were washed three times with PBS and permeabilized with Triton X-100 0.1%
in glycine 200 mM in PBS. Nonspecific binding was blocked with 3% of bovine
serum albumin (BSA) in PBS for 1 h. Fixed cells were incubated with the primary
antibody overnight at 4 °C, followed by 1.5 h incubation with the secondary anti-
body. Nuclei were stained with Hoechst 33342 (Life Technologies). Images were
taken using Zeiss Axio Imager Z1 microscope equipped with an Apotome device
(Carl Zeiss, Peabody, MA) and a motorized stage. Final images were bright contrast
adjusted with Zen 2012 (Carl Zeiss) or PowerPoint. Image quantifications were
performed with ImageJ with the MBF ImageJ bundle (http://www.
macbiophotonics.ca/imagej/installing_imagej.htm). For nuclear YAP the intensity
per nucleus was quantified by drawing a region of interest around nuclei and
calculating the average gray value per nucleus.
Quantitative PCR. RNA was extracted from exponentially growing cultures by the
TriZol method following manufacturer’s recommendations (Life Technologies).
Samples were excluded in cases were mRNA quality after processing was poor
(RIN < 7). One microgram total RNA was converted to cDNA using the Supre-
script III kit (Invitrogen). One microgram cDNA was used as input for the PCR
reactions. GAPDH was used for normalization.
Primers: FAT2 (Hs.PT.58.39666826), AXIN2 (Hs.PT.58.39305692). PrimeTime
qPCR assays were purchased from Integrated DNA Technologies (Coralville, IA).
A list of the primer sequences used for qPCR is present in the Supplementary
data 3.
Western blotting. Exponentially growing cells were washed in cold PBS, lysed on
ice in RIPA buffer (0.5% NaDOC, 0.1% SDS, 25 mM Hepes pH 7.5, 100 mM NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, 1% Triton X-100, 20 mM β-glycerophosphate,
0.5 mM DTT, 1 mM phenylmethylsulfonyl fluoride [PMSF], 1 × Complete Mini
Protease Inhibitor Cocktail (Roche, Indianapolis, IN)), and cell extracts collected,
sonicated, and centrifuged to remove the cellular debris. Supernatants containing
the solubilized proteins were quantified using the detergent compatible DC protein
estimation kit (Bio-Rad, Hercules, CA); equal amounts by mass were separated by
SDS-PAGE, and transferred to PVDF membranes (Millipore Corporation,
Billerica MA). Equivalent loading was confirmed with Ponceau-S staining. For
immunodetection, membranes were blocked for 1 h at room temperature in 5%
non-fat dry milk in T-TBS buffer (50 mM Tris/HCl, pH 7.5, 0.15 M NaCl, 0.1% [v/
v] Tween-20), followed by 2 h incubation with the appropriate antibodies, in 1%
BSA-T-TBS buffer. Detection was conducted by incubating the membranes with
horseradish peroxidase–conjugated goat anti-rabbit IgG secondary antibody
(Southern Biotech, Birmingham, AL, USA) at a dilution of 1:50,000 in 5% milk-T-
TBS buffer, at room temperature for 1 h, and visualized with Immobilon Western
Chemiluminescent HRP Substrate (Millipore). Uncropped versions of the western
blots in the main figures are shown in the Supplementary Fig. 9−11.
Cytometry. For apoptosis determination, the cells were trypsinized, washed once
with PBS, and fixed in 50% ethanol for 30 min at 4 °C. After fixation, the cells were
centrifuged, resuspended in a 1.12% sodium citrate, and 10 µg/mL RNase A in PBS
and incubated at 37 °C for 30 min. Propidium Iodide (PI) was added to a final
concentration of 50 µg/mL 5min before the analysis. Samples were analyzed in a
FACScalibur cytometer (Becton Dickinson, Franklin Lakes, NJ). For anti-CD4
staining, the cells were collected by incubation on PBS/EDTA/FBS (2 mM EDTA
and 0.005% FBS in PBS) until detached. The cells were washed once in PBS/BSA
(3% BSA in PBS), resuspended in blocking buffer (3% mouse serum in PBS) and
incubated for 20 min on ice. FITC-conjugated anti Human CD4 antibody (BD
Biosciences, San Jose, CA) was added (1:100) and incubated for 30 min on ice. The
cells were washed once with PBS/BSA and immediately analyzed in and FACS-
calibur cytometer.
Reporter assays. HEK293 cells were transfected in 24-well plates with 1 µg the
CD4 chimeric expression vectors in combination with 100 ng of a 8 × TEAD Firefly
luciferase reporter (Addgene ID 34615, Addgene, Cambridge, MA), 100 ng of a Pol
III-driven Renilla Reniformis Luciferase for normalization (pRL U6) and 100 ng of
pCEFL mCherry, an EF-1α driven mCherry expression vector to monitor trans-
fection efficiency. Luciferase activity was measured 24 h after transfection in a
Biotek Synergy Neo luminometer (Winooski, VT).
GST Pulldowns. GST-LATS1-142-704 was obtained by PCR amplification from
the vector p2xFlag CMV2 LATS1 (a gift from Marius Sudol) and cloned into
pGEX4T3 with adapters for BamHI and NotI. GST-FAT1-ICD was generated by
subcloning FAT1-ICD from pCEFL CD4-FAT1-ICD into the BamHI and NotI
sites of pGEX 4T3. Both GST fusion proteins, and GST as a control, were expressed
in BL21 E.coli transfected with each pGEX4T3 construct and coupled to GST-
Sheparose beads. To incubate the GST beads with mammalian cell extracts,
HEK293 cells were cultured in 15 cm plates and, upon reaching confluency, they
were quickly washed twice in ice-cold PBS and then lysed in pulldown buffer
(1 mL of 50 mM HEPES (pH 7.5), 150 mM NaCl, 10% glycerol, 0.3% (w/v)
CHAPS, 1.5 mM MgCl2, 1 mM EGTA, 100 mM NaF, 500 μM sodium orthovana-
date, 10 μg/mL aprotinin, and 10 μg/mL leupeptin and 1 mM PMSF). The pull-
down was performed by adding 20 µL of beads (or 10 µg of protein) to 1 mL of cell
lysate and incubated at 4 °C for 2 h with their corresponding GST beads
(Amersham, Piscataway, NJ). Beads were then washed three times with pulldown
buffer, resuspended in Laemmli sample buffer and resolved by SDS-PAGE.
Immunoprecipitation, kinase assay, and crosslinking. Exponentially growing
cultures in 150 mm plates were lysed in CHAPS buffer (1 mL of 50 mM HEPES
(pH 7.5), 150 mM NaCl, 10% glycerol, 6 mM CHAPS, 1.5 mM MgCl2, 1 mM
EGTA, 100 mM NaF, 500 μM sodium orthovanadate, 10 μg/mL aprotinin, and
10 μg/mL leupeptin and 1 mM PMSF). A volume of 15 µL of anti-CD4 antibody
(OKT4 clone, eBiosciences) and 20 µL of Gammabind G Sepharose beads
(GE Healthcare) were premixed in 500 µL CHAPS buffer and then combined with
the lysate and incubated on a rocker for 2 h at 4 °C. Beads were washed four times
with CHAPS buffer, once in wash buffer (40 mM HEPES, 200 mM NaCl), and once
in kinase assay buffer (30 mM HEPES, 50 mM potassium acetate, 5 mM MgCl2).
The immunoprecipitate was subjected to a kinase assay for 30 min at 30 °C in the
presence of 200 µM ATP and 100 ng of GST-MOB1A beads expressed and purified
in E. coli BL21 cells. Kinase reactions were stopped by resuspension in Laemmli
sample buffer and resolved by SDS-PAGE. Crosslinking experiments were per-
formed as described elsewhere41, differing in the immunoprecipitation step that
was performed as above.
Fig. 5 The YAP1 inhibitor Verteporfin (VP) impacts cell survival, proliferation, and tumor growth. a Dose-response experiment for cell viability as
determined by the AlamarBlue assay in CAL33 cell subjected to 48 h treatments with VP. Data points represent mean ± SEM (N= 8). b Gene expression
determination by quantitative PCR of YAP1 target genes CYR61, CTGF, and FSTL1 after 18 h treatment with 1 µM VP. Bars represent mean ± SEM (N= 4).
c Proliferation assay by cell counting of CAL33 cells exposed to vehicle (Control) or 1 µM VP for the times indicated. Data points represent mean ± SEM
(N= 4). d Apoptosis assay by propidium iodide staining. Dose-dependent VP-induced apoptosis at 48 h in CAL33 HNSCC cell. Data points represent
mean ± SEM (N= 3). e Spheroid formation assay of CAL33 cells treated with VP as indicated for 10 d. Representative pictures are shown on top, and
diameter quantifications (>95 colonies per group) are shown below. Black lines represent mean ± SEM. f In vivo tumorigenesis assay in nu/nu mice. One
million CAL33 cells were injected s.c. and tumors were allowed to grow until ~100mm3. Before treatment the animals were randomized so that the mean
tumor size per group was as equal as possible between groups at the initiation of treatment. Then VP was injected daily i.p. (50mg/Kg). Data points
represent mean tumor volume ± SEM (N= 10). g Representative immunohistochemical stainings of CAL33 tumors from panel (f). Scale bar, 100 µm.
h Automated histological quantification of BrdU staining in (g). Bars represent mean ± SEM (N= 5). i In vivo tumorigenesis assay by oral orthotopic
injection in SCID/NOD mice. Fifty thousand CAL33 cells were injected in the tongue, while VP was injected daily i.p. (50mg/Kg) starting 24 h after
implantation for the duration of the experiment. Right panel, representative gross appearance of the tumor lesions at collection time. Left panel, data
points represent mean tumor weight ± SEM (N= 10). j Representative immunohistochemical stainings of CAL33 tumors from panel i. Scale bar, 100 µm.
k Automated histological quantification of BrdU staining in (j). Bars represent mean ± SEM (N= 5). *P < 0.05, **P < 0.01, ***P < 0.001
(One-way ANOVA). l Scheme depicting the proposed molecular mechanism model, see text for details
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Spheroid formation. Spheroid (orosphere) assays were performed in 24-well
plates. Briefly, the wells were coated with 250 µL, 1.5%, agarose in DMEM. Ten
thousand cells were resuspended in 0.5 mL warm DMEM, 10% FBS, and 0.1%
agarose containing the appropriate treatment and layered on top. Agarose was
allowed to solidify at room temperature for 15 min before adding an additional
0.5 mL of DMEM, 10% FBS containing the same treatment as above, and returning
the cells to the incubator. The cells were allowed to grow for two weeks, replacing
the liquid media every three days before spheroid formation was analyzed. For
quantification, the wells were photographed using an automatic whole well scan
mode in a Zeiss Axiovert 200M microscope. Colony counting and diameter
measurements were performed manually using the Zeiss Axiovision 4.8 software.
Animal work. All animal studies were carried out according to NIH-approved
protocols, in compliance with the Guide for the Care and Use of Laboratory
Animals (http://www.iacuc.org/) and approved by the University of California San
Diego (UCSD) Institutional Animal Care and Use Committee (IACUC). All
handling, transplantation, and infection procedures were conducted in a laminar-
flow biosafety hood. Female athymic (nu/nu) nude mice (Harlan Sprague-Dawley,
Frederick, MD), 5–6 weeks of age and weighing 18–20 g, were used in the study,
and housed in appropriate sterile filter-capped cages and fed and watered ad
libitum. No randomization was used prior to experimental group assignment
except when indicated. Briefly, exponentially growing HNSCC cultures were har-
vested, washed, resuspended in DMEM, and 1 × 106 viable cells were transplanted
s.c. into both flanks of the athymic mice. For orthotopic injections, SCID/NOD
5–6 weeks of age female mice were used. Briefly, 1 × 105 resuspended in 50 µl of
DMEM were used and injected in the tongue from the ventral aspect of the tongue
following a posterior to anterior trajectory of the needle, so that the cells accu-
mulate toward the tip of the tongue. The investigators were not blinded to allo-
cation of samples during experiments and outcome assessment. For tumor growth
analysis, tumor weight was determined, whereby tumor volume ((LW2/2); were L
and W represent the length and the width of the tumor) was converted to weight
(mg) assuming unit density. No statistical method was used to estimate animal
sample size. The animals were monitored twice weekly for tumor development;42.
Results of animal experiments were expressed as mean ± SEM, and unpaired Stu-
dent’s t-test was used to determine the difference between experimental and
control groups for each of the transplanted cell lines. p < 0.05 was considered to be
statistically significant.
Proliferation and viability. Population doubling was calculated as described
elsewhere43. For viability assays, cells in either 96 well plates were treated as
indicated and supplemented with 1/10 of the culture volume of AlamarBlue
(Invitrogen, Carlsbad, CA) reagent for the last 6 h of the treatment. Absorbances
were recorded at 570 nm in a Biotek Synergy Neo microplate reader44.
Genomic data analysis. Gene mutation and copy number variation analyses were
performed using publicly available data generated by The Cancer Gene Atlas
(TCGA) consortium9, accessed through the UCSD Cancer Browser (genome-
cancer.ucsc.edu), the Memorial Sloan Kettering Cancer Center cBIO portal (www.
cbioportal.org), Broad’s Institute Firehose GDAC (gdac.broadinstitute.org/), GIS-
TIC (www.broadinstitute.org/tcga), and MutSigCV10 (www.tumorportal.org). The
copy number data for Hippo pathway genes in the TCGA pancancer was obtained
from the TCGA Copy Number Portal at the Broad Institute (http://portals.
broadinstitute.org/tcga/home). The mutational significance of Hippo pathway
genes in the TCGA pancancer dataset was obtained from the pancancer MUTSIG
results in the supplementary data 3 of Lawrence et al. 2013. The individual TCGA
cohort MUTSIG significance was obtained from FireBrowse release 20160128
(firebrowse.org). Gene expression analysis was performed with the Partek Geno-
mics Suite version 6.6 (Partek, St. Louis, MO). Gene enrichment analysis was
performed using the Enrichr software45. Custom python code used during the
TCGA analysis is available upon request.
REVEALER analysis. The REVEALER analysis finds mutually exclusive genomic
variants that correlate with a “functional” phenotype such as the activation of
YAP116. We used mutations and copy number alterations from the level 3 TCGA
HNSCC data from the Firehose Portal (https://gdac.broadinstitute.org/). The
REVEALER analysis included pre-filtered variants from the mutation and copy
number HNSCC TCGA datasets (a total of 1589 candidate genomic abnormalities).
The functional target for REVEALER was the mean normalized expression of
CTGF and CYR61 from the TCGA HNSCC RNASeq dataset. As the input “seed”
to REVEALER we used the amplification status of YAP1 (YAP1_AMP).
Statistical analysis. No statistical method was used to predetermine sample size.
The investigators were not blinded to allocation of samples during experiments and
outcome assessment. All analyses were performed in triplicate or greater and the
means obtained were used for ANOVA or independent, two-tailed, unpaired
t-tests. Statistical analyses, variation estimation, and validation of test assumptions
were carried out using the Prism 6 statistical analysis program (GraphPad).
Asterisks denote statistical significance (non-significant or N.S., p > 0.05; *p < 0.05;
**p < 0.01; and ***p < 0.001). All data are reported as mean ± standard error of the
mean (S.E.M).
Data availability. All data supporting the findings in this study are available from
the corresponding author upon reasonable request.
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